Further analyses revealed that gefitinib use remained a strong predictor for longer PFS and OS in EGFR‐TKI responders, adherent patients, adenocarcinoma patients, and adenocarcinoma patients receiving EGFR‐TKIs as second‐line therapy. The gene discussed is EGFR; the disease is adenocarcinoma.